Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute on Drug Abuse (NIDA)
With
Somerset Pharmaceuticals
The study objectives are to assess the efficacy and safety of the Selegiline Transdermal System (STS) in reducing cocaine use in subjects with cocaine dependence. It is hypothesized that selegiline treatment compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (BE).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male/Female
At least 18 years of age
DSM-4 diagnosis of cocaine dependence
Ability to understand and provide written consent
Female subjects must use acceptable birth control
You may not be if
\- Additional Criteria available during the screening process at the site.
